KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Assets: 2020-2025

Historic Assets for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $1.4 billion.

  • AbCellera Biologics' Assets fell 2.64% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 2.64%. This contributed to the annual value of $1.4 billion for FY2024, which is 8.57% down from last year.
  • AbCellera Biologics' Assets amounted to $1.4 billion in Q3 2025, which was down 3.29% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Assets ranged from a high of $1.6 billion in Q2 2022 and a low of $1.1 billion during Q1 2021.
  • Its 3-year average for Assets is $1.4 billion, with a median of $1.4 billion in 2024.
  • In the last 5 years, AbCellera Biologics' Assets spiked by 41.09% in 2022 and then declined by 8.57% in 2024.
  • AbCellera Biologics' Assets (Quarterly) stood at $1.3 billion in 2021, then increased by 16.86% to $1.5 billion in 2022, then dropped by 3.43% to $1.5 billion in 2023, then decreased by 8.57% to $1.4 billion in 2024, then decreased by 2.64% to $1.4 billion in 2025.
  • Its Assets was $1.4 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.3 billion in Q1 2025.